What the analyst said
UBS analyst Timothy Arcuri lowered the price target on NVIDIA (NASDAQ: NVDA) to $240 (from $300) while maintaining a Buy rating.
“We expect NVDA to beat FQ3 (Oct) revenue by ~$3-4B (e.g. as much as ~$111-112B) and we see FQ4 (Jan) revenue guidance in the ~$130B range (Street ~$125B) and revenue ultimately coming in even higher than this as Rubin remains on track to ramp substantially in FQ4.
This is despite delays for some rack components like rail kits – in other words, a similar situation to prior product generations where compute boards shipped in well ahead of the inflection in rack shipments (which should come in CQ1:27).
With the company having already soft-guided FQ4 gross margins to 71-72% (before rebounding starting in FQ1), there should be no surprises on margins. In the wake of this recent management shake-up last week, we heard many investors concerned about NVDA’s longer-term product roadmap – concerns that we find overblown as the ecosystem will continue to pull the roadmap along and any new CEO would almost certainly not want to risk competitive standing by moving away from the annual product cadence (though we still believe the new more dense Kyber racks are now off the table).
As for a new CEO, we believe the company will likely look to the semis and tech world, including potentially trying to hire from a competitor.
In addition to the potential for semis to undergo some correction given the mismatch between semis build plans and powered shell availability that we first highlighted in late September, our biggest concern now is new scrutiny that may restrict some of its sales into certain geographies such as Singapore/Malaysia.
In a worst case, we estimate this could cut up to ~10% out of revenue – in the near term though, we see no effect to estimates as demand still significantly exceeds supply. This could, however, be an issue for C2028 – especially as we are hearing more about delays in data center readiness/ availability.
As a result, we are cutting C2028E revenue/EPS from $985B/$22.08 to $885B/$20.01 – a cut of ~10% in terms of revenue. As for C2027, the company already soft-guided it to be up at least 70% Y/Y and we could see this maybe walked a bit higher as a symbolic show of strength (UBSe ~80%).
Lastly, in terms of valuation, everybody understands the stock is inexpensive, but when viewed through the UBS HOLT framework, this is particularly jarring. In essence, the market is assuming C2028 will be the peak, there will be no growth thereafter, and EBITDA margins will compress ~1,500bps – this seems incredibly draconian to us.
Net, we are trimming our PT on the back of the C2028 revenue cut, but we believe the near-term damage to the stock has been done and we don’t think it makes sense to give up on the stock after being down this much (as some of our peers have done last week) especially ahead of January hyperscaler earnings calls where we think CapEx will be guided higher than current Street expectations.
On a lower C2028E EPS, our PT goes from $300 to $240, obtained by applying a 12x NTM P/E multiple to our $20.01, and we view this pullback as an attractive buying opportunity, albeit one that may require some patience to let the management dust settle.”
The price target and rating on this page are the opinion of the issuing research firm and its analyst, not of Price Target. This page is published for informational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consider your own circumstances and consult a licensed financial adviser before making investment decisions.
This research note is reproduced verbatim from the issuing firm. Price Target never edits, paraphrases or alters analysts’ words — we only republish them in one place.
Where the price stands
NVDA trades at $163. The 33 analysts who set a target in the last 3 months range from $170 to $515, with a median of $240. This $240 target is in line with the median.
12-month window: day 0 of 365, closes on November 16, 2027.
Track record
This callOpen: a 12-month target, scored on November 16, 2027, a year after the note.
Firm track recordUBS: 81% of its 54 targets at least a year old were reached within 12 months (#8 of 28 firms); on NVIDIA, 6 of 6. Accuracy ranking →
UBS on NVIDIA
UBS price targets on NVIDIA
8 calls from March 17, 2026 to November 16, 2026. The target went from $245 to $240 (−2%). The rating stayed Buy.
- November 16, 2026 This noteTarget cut from $300 (−20%)Buy$240
- November 12, 2026Kept the $300 targetBuy$300
- October 9, 2026Kept the $300 targetBuy$300
- August 27, 2026Target raised from $280 (+7%)Buy$300
- August 14, 2026Target raised from $275 (+2%)Buy$280
- May 14, 2026Target raised from $245 (+12%)Buy$275
- May 11, 2026Kept the $245 targetBuy$245
- March 17, 2026Earliest call shownBuy$245





